Past investigations regarding the utility of high-sensitivity cardiac troponin I (cTnI) assays have been focused primarily on the acute coronary syndrome setting. We assessed whether such assays can predict future ischemic cardiovascular events in a stable high-risk population.
. Assay sensitivity also has a role in prognostication, in that low troponin concentrations exceeding the 99th percentile in and following an episode of acute coronary syndrome (ACS) identify patients at higher risk for an adverse event (3) (4) (5) (6) (7) . Recent studies have indicated that detectable concentrations of cardiac troponin below the 99th percentile may be used for longterm risk stratification (8 -13 ) . This finding was observed in both acute and nonacute settings, suggesting that low levels of cardiac troponin may have prognostic importance across the spectrum of cardiovascular disease (CVD).
Confusion remains, however, as to what constitutes a sensitive vs a high-sensitivity cardiac troponin assay (14 -16 ) . One metric that may be used to gauge analytical differences between cardiac troponin assays is the percentage of healthy individuals with measurable concentrations (14 ) . Specifically, in the proposed scorecard, a high-sensitivity assay can be stratified based on the percentage of measureable normal values below the 99th percentile (14 ) . This approach is in contrast to linking assay sensitivity with the precision at the 99th percentile, with assays (either contemporary or high-sensitivity) obtaining a 10% CV at the 99th percentile concentration being designated as guideline acceptable (14 ) . However, a recent statement from the biochemistry subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation task force for the definition of MI has suggested widening this estimate, allowing imprecision up to 20% at the 99th percentile concentration (17 ) . Thus, there is continued interest in understanding the prognostic implications of low cardiac troponin concentrations measured with these new, more analytically sensitive assays.
Most studies to date that have assessed both analytical and clinical issues related to high-sensitivity assays have considered only the high-sensitivity cardiac troponin T (hs-cTnT) assay (2, 7, (11) (12) (13) 18 ) . Preliminary reports for hs-cTnI assays have focused primarily on the analytical characteristics/performance (19 -23 ) , with only a few studies assessing health outcomes based on hs-cTnI concentrations in the ACS setting (24, 25 ) . No studies to date have assessed long-term cardiovascular outcomes with a hs-cTnI assay in a stable highrisk population. To address these issues, we evaluated and measured an investigational-use-only highsensitivity cardiac troponin I assay (hs-cTnI IUO) in a high-risk stable CVD population: the Heart Outcomes Prevention Evaluation (HOPE) study.
Methods

STUDY POPULATION AND OUTCOMES
The HOPE study population has been described (26 ) . Briefly, women and men who were stable were enrolled provided they met the following criteria: Ն55 years of age with a history of coronary artery disease, stroke, diabetes, or peripheral vascular disease (PVD) and at least 1 additional risk factor (e.g., smoking, hypertension, microalbuminuria, increased total cholesterol, or low HDL cholesterol) and without heart failure (26 ) . For this study, the study cohort comprised only those individuals (n ϭ 2572) in whom baseline serum was available stored frozen (Ϫ80°C) (27 ) . The outcomes used in this study were the primary outcome for the HOPE study: a composite of MI, stroke, or cardiovascular death (mean follow-up 4.5 years) as well as the individual outcomes: MI, stroke, and cardiovascular death alone as well as the combined outcome of MI/ cardiovascular death. Both C-reactive protein (CRP) and N-terminal pro-B-type natriuretic peptide (NTproBNP) were previously measured in this population, with information regarding the laboratory analysis reported elsewhere (27 ) . The study received Research Ethics Board approval.
hs-cTnI ANALYTICAL MEASUREMENTS
The Beckman Coulter hs-cTnI IUO assay used in this study (reagent lot 915790, calibrator lot 915791) has undergone modifications compared with the hs-cTnI prototype assay, similar to what has been done to their commercial assay (28 ) . Specifically, assay design was modified with a reduction in incubation time, use of recombinant alkaline phosphatase instead of native alkaline phosphatase, and a new buffer for the reagent pack. The preliminary 99th percentile for the hs-cTnI IUO assay (n ϭ 125 healthy individuals) was 9.5 ng/L (serum), 10.3 ng/L (heparin), and 9.5 ng/L (EDTA) (28 ) , consistent with previous estimates that listed the 99th percentile as 10 ng/L in those Ͻ60 years of age (24 ) . The precision (CV) for the hs-cTnI assay over the course of the study was 14.7% at a mean concentration of 14 ng/L (serum pool; n ϭ 86); 10.7% at 53 ng/L, and 8.5% at 650 ng/L (Bio-Rad Liquichek Cardiac Markers Plus Control LT; n ϭ 64).
The analytical characteristics of the Beckman Coulter prototype hs-cTnI assay have been reported (21 ) . Because the assay has been modified, however, the analytical characteristics of this assay were also investigated. Specifically, we also determined the limit of the blank (LoB), limit of detection (LoD), sample matrix comparison, and freeze-thaw effect on concentrations. For the LoB and LoD analyses, another lot of hs-cTnI (reagent lot 019032, calibrator lot 010737) was also tested (over 1 month) with the results combined to the previous lot data. During this time frame, the CV for the serum pool was 9.6% with the same mean concentration of 14 ng/L (n ϭ 17). We used 40 measurements of the zero calibrator to determine the LoB using the 95th percentile concentration (nonparametric) (21 ) . The overall mean for the serum pool was 14 ng/L, SD 1.6 ng/L (n ϭ 101 results). The LoD using these data was as follows: LoD ϭ LoB ϩ c␤(SD), as previously done for the prototype research hs-cTnI assay and consistent with Clinical Laboratory Standards Institute guidelines (21 ) .
We also compared the different matrices. Briefly, we measured 20 fresh matched samples for serum, lithium heparin, and EDTA plasma with the hs-cTnI assay (n ϭ 60) and performed Passing-Bablok regression analysis (Analyse-it software, version 2.12). After this analysis, the serum samples with sufficient volume remaining were subjected to 3 freeze-thaw cycles (n ϭ 18 samples; Ϫ70°C storage, 54 measurements) followed by Kruskal-Wallis testing to assess whether there were differences per freeze-thaw, with P values Ͻ0.05 considered significant (StatsDirect statistical software, version 2.7.7).
STATISTICAL ANALYSIS FOR HEALTH OUTCOMES
The primary outcome occurred in 406 of the 2572 subjects (15.7%), which is the same rate as was originally reported in the larger study (27 ) (see Supplemental  Table 1 , which accompanies the online version of this article at www.clinchem.org/content/vol57/issue8). ROC curve analysis was performed for the primary outcome (mean follow-up 4.5 years). For this, the hscTnI concentrations were logarithmically transformed and the Youden index used to identify the optimal value (i.e., the point that maximizes sensitivity and specificity). For consistency and comparability with other reported high-sensitivity cardiac troponin assays, we used only integers (i.e., whole numbers) for these analyses (29 ) . We used integer values from ROC analyses (derived from both study population and published concentrations) and 99th percentile (Ն10 ng/L) as the cutoffs, with both Kaplan-Meier (with log-rank statistic) and Cox proportional hazard analyses. Cox models were adjusted for sex and age (model 2), for variables that were univariately significant for the primary outcome [i.e., age, sex, diabetes, current smoker, HDL cholesterol (log-transformed) and PVD] (model 3), as well as for other important variables including age, sex, diabetes, smoking, HDL (log-transformed), PVD, lipid-lowering agent, ramipril, systolic blood pressure, CRP (log-transformed), and NT-proBNP (log-transformed) (model 4).
We performed a secondary analysis for each outcome alone based on the following 3 groups classified by hs-cTnI concentrations: Ͻ6 ng/L (below the ROC cutoff); Ն10 ng/L (above 99th percentile); and in between (i.e., 6 to Ͻ10 ng/L). Kaplan-Meier and Cox proportional hazard analyses were performed over the study timeframe (models 3 and 4) for each outcome, with the Ͻ6 ng/L group being the referent group. Multivariate logistic models (including variables in model 3) with and without hs-cTnI (log-transformed) were performed to obtain the c statistic for the primary outcome (i.e., composite outcome), as well as for MI alone, stroke alone, and cardiovascular death alone, to assess the discriminative value of hs-cTnI for these outcomes.
We also performed a tertiary analysis on the combined endpoint of MI/cardiovascular death. For this, we used Cox proportional hazard analysis for those subjects that had NT-proBNP, CRP, and hs-cTnI measurements. The biomarkers were evaluated based on previous derived cutoffs (NT-proBNP Ͼ156 ng/L and CRP Ͼ6 mg/L) (27 ) and the 99th percentile for hscTnI (Ն10 ng/L), in an established risk factor model (variables included age, systolic blood pressure, antihypertensive treatment, lipid-lowering treatment, diabetes, smoking status, body mass index, log total cholesterol, and log HDL (30 ); n ϭ 2491). This model was chosen because both CRP and NT-proBNP were previously evaluated in this model for the prediction of cardiovascular death in an older community cohort. Estimates of the c statistic (Harrell's c) were then derived from these models, but including only the biomarkers (CRP, NT-proBNP, and hs-cTnI) that were significant. Categorical variables were tested by Pearson 2 test and continuous variables with nonparametric methods. Analyses were performed in SAS version 9.1 (SAS Institute) and STATA 10.0 (Stata Corp), with P values Ͻ0.05 considered significant.
Results
In our laboratory, the hs-cTnI IUO assay LoB was determined to be Ͻ0.5 ng/L (0.44 ng/L) with the derived LoD of 3 ng/L (3.08 ng/L). Passing-Bablok regression analyses yielded the following relationships between the matrices: EDTA hs-cTnI ϭ 1.06(serum hs-cTnI) Ϫ 0.17; heparin hs-cTnI ϭ 1.19(serum hs-cTnI) Ϫ 0.98). There was no significant effect on hs-cTnI (range of concentrations 3-32 ng/L) after 3 freeze-thaw cycles (P ϭ 0.22). In the HOPE study cohort, men had a higher prevalence of CVD and higher hs-cTnI concentrations than women ( Table 1) . Concentrations of hscTnI were not normally distributed (Shapiro-Wilk P Ͻ 0.001), with approximately 4% of the results below the limit of detection (i.e., Ͻ3 ng/L) (Fig. 1) . The area under the ROC curve (AUC) for hs-cTnI for the primary outcome (composite of MI/stroke/cardiovascular death) was 0.625 (95%CI 0.595-0.655). The optimal concentration for predicting the primary outcome in the HOPE cohort was 6 ng/L, with those below this concentration having a lower probability for the outcome based on Kaplan-Meier analysis (P Ͻ 0.001) (Fig. 2) .
Next, we explored the utility of using the published 99th percentile concentration cutoff for risk stratification in this population (i.e., 10 ng/L). Based on the 99th percentile, there was also a significant difference in rates for the primary outcome (P Ͻ 0.001) (Fig.  2) . Cox proportional hazard models assessing the ROC cutoff (6 ng/L) and 99th percentile (10 ng/L) indicated that those above the cutoffs were at significant risk for the primary outcome compared with those below the cutoffs, after adjusting for clinical variables including both CRP and NT-proBNP [hazard ratio (HR) 1.4, P Ͻ 0.01] ( Table 2) .
Assessing the distribution of hs-cTnI values based on these cutoffs identified nearly 50% of the study participants (n ϭ 1279) with concentrations Ͻ6 ng/L, with 22% (n ϭ 567) having concentrations above the 99th percentile (Ն10 ng/L) and the remainder having hs-cTnI concentrations 6 to Ͻ10 ng/L (n ϭ 726). Kaplan-Meier analysis was undertaken to determine the event rate between the 3 groups for each outcome (i.e., MI alone, stroke alone, and cardiovascular death alone; see Fig. 3 ). There were significant differences between the 3 groups for MI (P Ͻ 0.001), stroke (P ϭ 0.007), and cardiovascular death (P Ͻ 0.001). Cox proportional hazard analyses were performed to assess the risks for the 6 to Ͻ10 ng/L group and Ն10 ng/L group compared with the Ͻ6 ng/L group (Table 3) . After adjustment for the important variables, subjects with hscTnI concentrations 6 to Ͻ10 ng/L or Ն10 ng/L were at equivalent risk for MI (HR 1.5, P Ͻ 0.03); those with hs-cTnI Ն10 ng/L were at a higher risk for cardiovascular death (HR 2.2, 95% CI 1.3-3.5; P ϭ 0.002). Neither hs-cTnI group was at higher risk for stroke compared with those with hs-cTnI Ͻ6 ng/L ( Table 3) . Next we determined the discriminative value of hs-cTnI for the different outcomes. The c statistic for the primary outcome was increased when hs-cTnI was included in the model (c ϭ 0.672 with hs-cTnI vs 0.653 without; P ϭ 0.004). Assessing the individual outcomes showed that inclusion of hs-cTnI significantly increased the c statistic compared with models without for cardiovascular death (0.742 vs 0.709; P Ͻ 0.001) and MI (0.637 vs 0.597; P Ͻ 0.001), but not stroke (0.664 vs 0.661; P ϭ 0.683).
As hs-cTnI appeared to provide prognostic information for only MI and cardiovascular death, we next evaluated hs-cTnI for the combined outcome MI/cardiovascular death in the context of established risk factors and biomarkers for cardiovascular disease (30 ) . In these models, after adjusting for the established risk factors, only NT-proBNP (HR 2.14, 95% CI 1.69 -2.73; P Ͻ 0.001) and hs-cTnI (HR 2.16, 95% CI 1.73-2.70; P Ͻ 0.001) remained significant, whereas CRP was not (HR 1.13, 95% CI 0.88 -1.44; P ϭ 0.346) (Supplemental Table 2 ). Inclusion of hs-cTnI in the model that included these established risk factors and NT-proBNP increased the c statistic compared with the model without hs-cTnI for the combined outcome (0.680 vs 0.659; P ϭ 0.020).
Discussion
The present study is the first report demonstrating the prognostic significance of measuring hs-cTnI in a highrisk, stable population. Importantly, this study demonstrates for the hs-cTnI assay that concentrations below the reported 99th percentile from a healthy population can identify individuals at risk for an ischemic event. These data are different from the other studies in the literature assessing hs-cTnT, in that either MI or stroke was not used as an outcome in those populations (12, 13 ) or the study assessed MI and failed to show a risk for this event with respect to hs-cTnT concentrations (11 ) . Additional studies are warranted to address the role of the high-sensitivity assays in predicting ischemic cardiovascular outcomes in the nonacute, stable CVD population.
Our findings also raise important questions regarding what cutoff should be used in the non-ACS setting for long-term risk stratification (31 ) . For the hs-cTnI assay, analysis of data from 3 different populations (including the present study) using ROC analyses suggests a possible lower cutoff than the 99th per- centile (24, 32 ) . For example, Venge et al. (24 ) identified 6.4 ng/L as the optimal cutoff to discriminate healthy individuals from those with ACS. Furthermore, individuals with hs-cTnI concentrations Ն6 ng/L had a higher rate of death at 1 year (8.1%) than those with concentrations Ͻ6 ng/L (3.0%), as did those with concentrations Ն10 ng/L (24 ). However, the risk for those ACS patients with hs-cTnI concentrations above the ROC cutoff and below the 99th percentile (i.e., 6 -10 ng/L) was not assessed in that study (24 ) . Schulz et al. (32 ) , measuring hs-cTnI in patients with stable CVD, identified 6.75 ng/L as the best concentration for predicting the type of chronic heart disease; however, ROC concentrations were not predictive of events in that smaller study. In the present study, 6 ng/L was identified as the optimal concentration for predicting the primary outcome. On further analysis, however, it appears that this effect was driven mainly by MI and cardiovascular death. Assessing CRP, NT-proBNP, and hs-cTnI in this population for the combined outcome (MI/cardiovascular death) revealed that only increased NT-proBNP and hs-cTnI were significant risk factors; addition of hs-cTnI to a model including NTproBNP resulted in a higher c statistic. This is similar to findings for the Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) study, where addition of hs-cTnT to a model including NT-proBNP resulted in a higher c statistic. It is worthy to note that in the HOPE population, increased CRP was not related to future MI, but was associated with future stroke (27 ) , perhaps explaining the nonsignificant findings for CRP for MI/cardiovascular death. Analytically, this newer version of the hs-cTnI assay (hs-cTnI IUO) appears to have retained attributes similar to those of the prototype assay, although the estimates for both the LoB and LoD are slightly different (example, hs-cTnI IUO assay LoD ϭ 3 ng/L compared to prototype LoD ϭ 2 ng/L). A larger study assessing multiple lots of reagents may be required to obtain a more thorough analytical description of this assay and its precision below the 99th percentile. Importantly, almost all individuals had measurable concentrations using the hs-cTnI IUO assay, which is perhaps the most important aspect, as this allowed health outcome analysis exploring different cutoffs.
Finally, additional work is required in various clinical settings to ascertain the impact of this testing. This is especially important considering the modest, albeit significant, incremental effect of the addition of hscTnI to models for MI and cardiovascular death. Furthermore, outcome studies relating treatment to hs-cTnI concentrations are required, as well as understanding what a significant change in concentration would be in this setting for individuals with serial measurement. One approach would be to use biological variation to ascertain what would constitute a difference in serial measurements longitudinally in the chronic setting (33, 34 ) , or alternatively, an assessment of the minimum concentration change that translates to an adverse outcome. These data are beginning to emerge in the ACS setting (35, 36 ) ; however, the criteria for change in both chronic and acute settings will most likely be different, as recently demonstrated with hs-cTnT assay (12 ) . Further studies addressing these important points are required before these highsensitivity assays are used for screening large populations at risk (37 ) .
